1 / 9

Simeprevir in HIV Coinfection, GT-1 C212 Trial

Phase 3. HIV Coinfection. Treatment Naïve and Treatment Experienced. Simeprevir in HIV Coinfection, GT-1 C212 Trial. Dieterich D , et al. Clin Infect Dis. 2014;59:1579-87. Simeprevir + PEG + Ribavirin for HCV-HIV Coinfection Study C212: Study Features.

keita
Download Presentation

Simeprevir in HIV Coinfection, GT-1 C212 Trial

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Phase 3 HIV Coinfection Treatment Naïve and Treatment Experienced Simeprevir in HIV Coinfection, GT-1C212 Trial DieterichD, et al. Clin Infect Dis. 2014;59:1579-87.

  2. Simeprevir + PEG + Ribavirin for HCV-HIV CoinfectionStudy C212: Study Features Source: Dieterich D, et al. Clin Infect Dis. 2014;59:1579-87.

  3. Simeprevir + PEG + Ribavirin for HCV-HIV CoinfectionStudy C212: Design 0 12 24 48 Week Simeprevir Peginterferon+ Ribavirin Treatment-NaïveorPrior Relapse Response Guided Therapy Simeprevir Peginterferon+ Ribavirin Partial ResponseorNull Response Simeprevir Peginterferon+ Ribavirin Drug DosingSimeprevir: 150 mg once dailyPeginterferon alfa-2a (PEG): 180 mcg/week Ribavirin (RBV) weight-based (in 2 divided doses): 1000 mg if < 75kg or 1200 mg/day if ≥ 75kg Source: Dieterich D, et al. Clin Infect Dis. 2014;59:1579-87.

  4. Simeprevir + PEG + Ribavirin for HCV-HIV CoinfectionStudy C212: Results C212: SVR12 by Prior Treatment Status 78/106 42/53 13/15 7/10 16/28 Treatment-Experienced Source: Dieterich D, et al. Clin Infect Dis. 2014;59:1579-87.

  5. Simeprevir + PEG + Ribavirin for HCV-HIV CoinfectionStudy C212: Results C212: SVR12 by GT1 Subtype and Baseline NS3 Q80K Polymorphism 16/18 62/88 20/30 42/58 Source: Dieterich D, et al. Clin Infect Dis. 2014;59:1579-87.

  6. Simeprevir + PEG + Ribavirin for HCV-HIV CoinfectionStudy C212: Results C212: SVR12 by Fibrosis Stage and Prior History 36/45 14/22 24/27 4/7 7/9 2/2 1/2 2/3 4/7 6/10 Treatment-Experienced Source: Dieterich D, et al. Clin Infect Dis. 2014;59:1579-87.

  7. Simeprevir + PEG + Ribavirin for HCV-HIV CoinfectionStudy C212: Results C212: SVR12 by IL28B Genotype 0/2 27/28 40/59 11/18 15/15 19/27 8/10 7/7 6/6 1/1 5/7 1/2 4/5 10/19 2/4 Treatment-Experienced Source: Dieterich D, et al. Clin Infect Dis. 2014;59:1579-87.

  8. Simeprevir + PEG + Ribavirin for HCV-HIV CoinfectionStudy C212: Conclusions Source: Dieterich D, et al. Clin Infect Dis. 2014;59:1579-87.

  9. This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Onlinewww.hepatitisc.uw.edu Hepatitis Web Studyhttp://depts.washington.edu/hepstudy/ Funded by a grant from the Centers for Disease Control and Prevention.

More Related